We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Bariatric Embolization Could Promote Weight Loss

By HospiMedica International staff writers
Posted on 13 Dec 2015
An experimental percutaneous procedure which involves embolization of the left gastric artery can lead to 50% reductions in excess weight, according to a new study. More...


Researchers at Dayton Interventional Radiology (OH, USA) performed the percutaneous procedure—dubbed bariatric or gastric artery embolization—using Bead Block, a formulation of tiny polyvinyl alcohol hydrogel microspheres that is made by Infiniti Medical (Menlo Park, CA, USA). The microspheres are tinted blue to improve visualization and come in a variety of sizes and preloaded syringes to facilitate targeted embolization of tumors and vascular malformations. Prior to use, Bead Block is mixed with an iodinated contrast agent and injected under fluoroscopic guidance.

The results showed that following embolization, one patient underwent a weight loss of nearly 20 kg (48.6% of her excess body weight); another patient, who was a diabetic, lost 12 kg (17% of her excess body weight) after the procedure, and a third lost 5 kg. A fourth patient lost only two and a half kilograms, but according to the researchers suffered a depressive event during the trial, and may have overeaten to compensate. The study was presented at the Radiological Society of North America (RSNA) annual meeting, held during November–December 2015 in Chicago (IL, USA).

“Bariatric embolization is a promising treatment for obesity. It can be performed on an outpatient basis and has the potential to provide as much weight loss as is seen in gastric surgery,” said lead author and study presenter Mubin Syed, MD. He added that the researchers believe that gastric artery embolization reduces ghrelin—the “hunger hormone”—and that embolization of the left gastric artery does not appear to harm the stomach because the organ has a rich collateral blood supply.

The experimental percutaneous procedure was conducted in four morbidly obese patients under a US Food and Drug Administration (FDA) experimental device exemption to determine if the larger Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GETLEAN) study, which is currently recruiting, should be expanded. The pilot study will enroll morbidly obese patients with a body mass index (BMI) higher than 40 kg/m2 who are otherwise healthy. Patients must also have failed previous attempts at weight loss through diet, exercise, and behavior modification.

Related Links:

Dayton Interventional Radiology
Infiniti Medical



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
New
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: 123RF

AI Platform Screens for Amyloid Cardiomyopathy Using ECG Images

Amyloid cardiomyopathy is a heart disease caused by deposits of misfolded proteins in the cardiac muscle. It is often missed until patients develop serious complications such as heart failure.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.